Metrics to compare | MNOV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNOVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.7x | 3.3x | −0.2x | |
PEG Ratio | −0.73 | 0.01 | 0.00 | |
Price/Book | 1.9x | 2.6x | 2.6x | |
Price / LTM Sales | 78.1x | 4.3x | 2.8x | |
Upside (Analyst Target) | - | 380.3% | 60.9% | |
Fair Value Upside | Unlock | 29.3% | 9.5% | Unlock |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.